As several news reports have showed, the Indian regulator too probed Ranbaxy after the US FDA's charges came to the fore in 2008 but it was under-policed and half-baked to say the least. The investigation was dropped mid way when the Indian regulators saw that the UK and Australian regulators did not ban Ranbaxy drugs. The US media has already begun castigating the US government and the FDA for not being stringent enough. T his story in Fortune details the sordid tale and questions how "Ranbaxy is in business in the United States".